Topical application of antisense oligonucleotide-loaded chitosan nanoparticles to rats

Oligonucleotides

Volumn 20, Issue 3, 2010, Pages 147-153

  Özbaş Turan, Suna ^a   Akbuǧa, Jülide ^a   Sezer, Ali Demir ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CHITOSAN; NANOPARTICLE; TRIPOLYPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HISTOPATHOLOGY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKIN; SPRAGUE DAWLEY RAT; ANIMAL; TOPICAL DRUG ADMINISTRATION;

ANIMALIA; RATTUS;

ADMINISTRATION, TOPICAL; ANIMALS; CHITOSAN; FEMALE; MALE; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77954131966     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2009.0222     Document Type: Article

References (26)

1. ÄKBUGA, J., and OZBAŞ-TURAN, S. (2006). Comparison of chitosan-based systems for skin gene delivery. Abstracts XIV. Annual Congress of The European Society of Gene Therapy, p. 42, 9-12 November, Athens, Greece.
2. BANCROFT, J.D., and GAMBLE, M. (2003). Theory and practice of histological techniques. Fifth Edition, Churchill Livingstone, London.
3. BRADFORD, M.A. (1976). Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
4. BRAND, R.M., and IVERSEN, P.L. (2000). Transdermal delivery of antisense compounds. Adv. Drug Deliv. Rev. 44, 51-57.
5. CALVO, P., REMUNAN-LOPEZ, C., VILA-JATO, J.L., and ALONSO, M.J. (1997). Chitosan and chitosan=ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14, 1431-1436.
6. DINAUER, N., LOCHMANN, D., DEMIRHAN, I., BOUAZ-ZAOUI, A., ZIMMER, A., CHANDRA, A., KREUTER, J., and VON BRIESEN, H. (2004). Intracellular tracking of prot-amine=antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation. J. Control. Release 96, 497-507.
7. DOKKA, S., COOPER, S.R., KELLY, S., HARDEE, G.E., and KARRAS, J.G. (2005). Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin. J. Invest. Dermatol. 124, 971-975.
8. DONG, L., ZUO, L., XIA, S., GAO, S., ZHANG, C., CHEN, J., and ZHANG, J. (2009). Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis. J. Gene Med. 11, 229-239.
9. DUNG, T.H., LEE, S.R., HAN, S.D., KIM, S.J., JU, Y.M., KIM, M.S., and YOO, H. (2007). Chitosan-TPP nanoparticle as a release system of antisense oligonucleotide in the oral environment. J. Nanosci. Nanotechnol. 7, 3695-3699.
10. ENNELI, B., SALVA, E., and AKBUGA, J. (2006). Development of a novel delivery system for antisense oligonucleotides. The 31th FEBS Congress, 24-29 June, Istanbul, Turkey.
11. GAO, S., CHEN, J., DONG, L., DING, Z., YANG, Y.H., and ZHANG, J. (2005). Targeting delivery of oligonucleotide and plasmid DNA to hepatocyte via galactosylated chitosan vector. Eur. J. Pharm. Biopharm. 60, 327-334.
12. HENGGE, U.R., WALKER, P.S., and VOGEL, J.C. (1996). Expression of naked DNA in human, pig, and mouse skin. J. Clin. Invest. 97, 2911-2916.
13. HONG, H.J., JIN, S.E., PARK, J.S., AHN, W.S., and KIM, C.K. (2008). Accelerated wound healing by smad3 antisense oli-gonucleotides-impregnated chitosan=alginate polyelectrolyte complex. Biomaterials 29, 4831-4837.
14. HUSSAIN, M., BEALE, G., HUGHES, M., and AKHTAR, S. (2002). Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glyco-lide) microsphere formulations for potential combination therapy in cancer. Int. J. Pharm. 234, 129-138.
15. LEWIS, K.J., IRWIN, W.J., and AKHTAR, S. (1998). Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro. J. Drug Target. 5, 291-302.
16. MAYER, G., VOGEL, V., WEYERMANN, J., LOCHMANN, D., VAN DEN BROEK, J.A., TZIATZIOS, C., HAASE, W., WOUTERS, D., SCHUBERT, U.S., ZIMMER, A., KREUTER, J., and SCHUBERT, D. (2005). Oligonucleotide-protamine-albumin nanoparticles: protamine sulfate causes drastic size reduction. J. Control. Release 103, 99-111.
17. MEHTA, R.C., STECKER, K.K., COOPER, S.R., TEMPLIN, M.V., TSAI, Y.J., CONDON, T.P., BENNETT, C.F., and HARDEE, G.E. (2000). Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. J. Invest. Dermatol. 115, 805-812.
18. ŔEGNIER, V., LE DOAN, T., and PREAT, V. (1998). Parameters controlling topical delivery of oligonucleotides by electro-poration. J. Drug Target. 5, 275-289.
19. ŔEGNIER, V., and PREAT, V. (1998). Localization of a FITC-labeled phosphorothioate oligodeoxynucleotide in the skin after topical delivery by iontophoresis and electroporation. Pharm. Res. 15, 1596-1602.
20. SPRINGATE, C.M.K., JACKSON, J.K., GLEAVE, M.E., and BURT, H.M. (2005). Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother. Pharmacol. 56, 239-247.
21. SPRINGATE, C.M.K., JACKSON, J.K., GLEAVE, M.E., and BURT, H.M. (2008). Clusterin antisense complexed with chitosan for controlled intratumoral delivery. Int. J. Pharm. 350, 53-64.
22. TEZEL, A., DOKKA, S., KELLY, S., HARDEE, G.E., and MI-TRAGOTRI, S. (2004). Topical delivery of anti-sense oligo-nucleotides using low-frequency sonophoresis. Pharm. Res. 21, 2219-2225.
23. WHITE, P.J., FOGARTY, R.D., WERTHER, G.A., and WRAIGHT, C.J. (2000). Antisense inhibition of IGF receptor expression in HaCaT keratinocytes: a model for antisense strategies in keratinocytes. Antisense Nucleic Acid Drug Dev. 10, 195-203.
24. WHITE, P.J., GRAY, A.C., FOGARTY, R.D., SINCLAIR, R.D., THUMIGER, S.P., WERTHER, G.A., and WRAIGHT, C.J. (2002). C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application. J. Invest. Dermatol. 118, 1003-1007.
25. WRAIGHT, C.J., and WHITE, P.J. (2001). Antisense oligonucle-otides in cutaneous therapy. Pharmacol. Ther. 90, 89-104.
26. WRAIGHT, C.J., WHITE, P.J., MCKEAN, S.C., FOGARTY, R.D., VENABLES, D.J., LIEPE, I.J., EDMONDSON, S.R., and WERTHER G.A. (2000). Reversal of epidermal hyperproli-feration in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat. Biotechnol. 18, 521-526.